Ignite Creation Date:
2025-12-24 @ 3:49 PM
Ignite Modification Date:
2025-12-25 @ 1:56 PM
Study NCT ID:
NCT04517292
Status:
UNKNOWN
Last Update Posted:
2020-08-18
First Post:
2020-08-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
Sponsor:
Fudan University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-10-08
Start Date Type:
ESTIMATED
Primary Completion Date:
2022-07-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-10-31
Completion Date Type:
ESTIMATED
First Submit Date:
2020-08-16
First Submit QC Date:
None
Study First Post Date:
2020-08-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-08-16
Last Update Post Date:
2020-08-18
Last Update Post Date Type:
ACTUAL